Trust Is the Only Moat Left in Aesthetics
Reputation is the one asset that compounds — or collapses.
There is a fact about the aesthetics market that ought to embarrass it more than it does. The leading product in nearly every major injectable category is old. In several cases it is old enough to have been on the market longer than some of the injectors now using it have been alive, and the industry has grown so accustomed to this that it has stopped finding it strange. The dominant neurotoxin, the dominant volumizing filler, the dominant collagen stimulator: in category after category, the product at the top is measured in decades rather than years. It has held that position through wave after wave of newer entrants, each arriving with better specifications, cleaner data, more modern formulations, and the full conviction that superior science would be enough to dislodge it. It never is. The comfortable explanation is that incumbents win on brand inertia and marketing budget, that the leaders are simply coasting on recognition and outspending their challengers. There is a grain of truth in that, and it mistakes the residue of the real mechanism for the mechanism itself. What keeps these products on top is the thing their age allowed them to accumulate.
Finish the essay. Join the MargaZine.
The MargaZine is free. One email unlocks the full library and brings every Monday drop to your inbox. No spam; unsubscribe anytime.
Better on paper, worse on a face
The newer entrant is almost always sold on the premise that it is better, and on a specification sheet it frequently is. It offers a longer duration figure, a smoother rheology, a cleaner side-effect profile, or some other genuine improvement that looks decisive in a comparison table, and it arrives expecting the market to reward that improvement the way most markets reward a better product. Aesthetics does not work that way. The product is not consumed on a specification sheet. It is applied to a human face and judged, emotionally and visually, by a person who cares far less about the theoretical superiority of the molecule than about whether the result will be predictable. Predictability is a property no amount of laboratory advantage can confer on a product the day it launches. The incumbent's real asset is the accumulated, distributed knowledge of exactly how it behaves. Thousands of injectors know precisely how it settles and diffuses and ages across every anatomy and every dose. That is a body of hard-won practical familiarity no newcomer can carry onto the market, no matter how good its data. That knowledge is not manufactured in a lab or purchased with a launch budget. It is deposited, slowly, one predictable result at a time.
The compounding ladder
The mechanism underneath all of this is worth laying out plainly, because it explains not only why old products win but why the advantage widens rather than decays over time. A product enters the world with novelty. Novelty generates interest, interest produces trial, and at that point the two possible futures diverge entirely on a single variable, which is consistency. The product that performs the same way every time converts trial into habit, habit into trust, and trust, eventually, into the status of default choice, the thing an injector reaches for without deliberating because it has earned the right to be assumed. Here is the property the challengers consistently underestimate. Novelty depreciates while trust appreciates. The moment a new product is no longer new, its central selling point has already begun to decay. Every uneventful, predictable, unremarkable result the incumbent produces adds another deposit to a reserve of confidence that grows more valuable precisely because it is so slow to build. The newcomer is spending down an asset that fades. The incumbent is compounding one that accrues. Time, which the challenger treats as an enemy to be outrun with better features, is the incumbent's most productive employee.
The launch mistake this creates, and why leadership keeps making it
If trust is the real asset, and trust can only be accumulated slowly through consistency rather than purchased quickly through performance, then the correct way to launch in this category follows directly and uncomfortably. You should be willing to move more slowly than your instincts demand. Prioritize the depth of clinical understanding and the quality of early adoption over the speed of early profit. Accept a gentler revenue curve now in exchange for laying down the reserve of predictable results and injector familiarity that will make the product durable for the fifteen years after. This is the strategy the market's own history most clearly rewards, and it is almost never the strategy that gets chosen. The people making launch decisions are measured on near-term numbers, compensated on near-term numbers, and answerable to boards and investors who want the return to arrive on a schedule that has nothing to do with how trust actually forms. So leadership does the reverse of what the category rewards. It harvests early demand aggressively while starving the patient, unglamorous work of building deep adoption. In doing so it trades a durable, compounding asset for a short-term figure, over and over, in one of the most expensive recurring mistakes in the entire industry. Companies know better. The tragedy is that the incentives make knowing better almost useless.
The counterintuitive corollary
There is a corollary here that sounds wrong until you sit with it. The best moment to invest in a product's trust is very often the exact moment the P&L is telling you to harvest it. The pressure to extract near-term value is heaviest precisely when a product is gaining traction, which is also precisely when the deposits into its reserve of trust compound most powerfully. The discipline that separates a durable franchise from a product that flares and fades is the willingness to keep investing in adoption depth and clinical understanding through the window when it would be easiest, and most immediately profitable, to stop. That discipline is rare, because it requires a leadership team to defend a slower curve against every incentive pointing the other way. The companies that manage it are the ones whose products still lead the category two decades later, described, a little dismissively, as old, as though age were the accident rather than the achievement.
The single most valuable and least respected asset in aesthetics is predictability, and predictability is the one thing money genuinely cannot buy on any timeline shorter than years. So the entire strategic posture of a company in this category should be organized around the patient accumulation of trust rather than the rapid demonstration of superiority. Innovation depreciates and trust appreciates. A firm that understands this stops asking only whether its product is better. It starts asking whether it is building the kind of consistency that becomes a default. In a market where the customer judges by feel and rebooks by confidence, the default choice is worth more than the superior one. The old products win because of everything their age let them quietly compound, while their challengers kept mistaking novelty for advantage.
Questions worth sitting with
Any team preparing a launch, or defending a franchise, would benefit from a few questions the quarterly rhythm tends to crowd out.
- Are you competing on a superiority your customers can feel, or only on one your spec sheet can prove?
- What is your product's reserve of trust actually made of, and are your launch decisions building it or spending it down?
- Are you harvesting early demand at the cost of the adoption depth that would make the product durable, and do you know the true price of that trade?
- And the question that reframes an entire launch: are you optimizing for the return that lands this year, or for the compounding that keeps a product dominant in fifteen, because in this category those two goals are frequently at war, and only one of them builds something that lasts.
The trust-compounds problem sits at the center of how launches should be run and how franchises should be defended. Helping leadership teams resist the pull of the near-term number long enough to build the slow, durable asset that actually wins this category is a substantial part of what I do, particularly with companies preparing a launch or trying to understand why a genuinely superior product has failed to displace an older, lesser one. If you are betting on being better and quietly watching an incumbent refuse to lose, the reason is probably not your data, and that is a conversation worth having before the launch curve is set.
Schedule a consultationA pharmacist turned commercial leader who has followed products across the entire value chain — from clinical development to launch, loyalty, and lifecycle — at three of the industry’s largest names.
Work with Marga →References & further reading
- Brand trust, habit, and switching costs as durable competitive advantage (customer-retention and brand-equity literature). Market coverage — incumbency & loyalty in aesthetics.
The frameworks and commercial analysis here are Marga Partners’ own; the factual claims rest on the sources cited.